Drug Development Pipeline
ABBV-2222 + ABBV-3067 + ABBV-576
Restore CFTR Function
This program is studying a combination therapy combining three CFTR modulators, two correctors and a potentiator. Correctors are a type of modulator designed to fix the defective CFTR protein so that it can move to the proper place on the cell surface. Once CFTR protein reaches the cell surface, potentiators help facilitate the opening of the chloride channel to allow chloride and sodium (salt) to move in and out of the cell.
A phase 2 study to test the safety and effectiveness of ABBV-3067 both alone and in combination with ABBV-2222 is currently underway. Future studies will test ABBV-3067 and ABBV-2222 in combination with a third modulator, ABBV-576, to form a triple-combination therapy.
This program is sponsored by Abbvie and is being conducted within the Therapeutics Development Network.
Recent ABBV-2222 + ABBV-3067 + ABBV-576 Studies
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More